NCT00184041View on ClinicalTrials.gov

Intensified Post Remission Therapy Containing PEG-Asparaginase

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2012

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine

Induction I/II, consolidation I/II/III/IV and Maintenance

Trial Locations (1)

90032

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

All Listed Sponsors
lead

University of Southern California

OTHER

NCT00184041 - Intensified Post Remission Therapy Containing PEG-Asparaginase | Biotech Hunter | Biotech Hunter